B and BIOA Related Headlines
Go Back- Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
- Bulletin from the Annual General Meeting in BioArctic AB (publ)
- BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day
- Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)
- Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET
- FDA extends Leqembi Iqlik review period to August 24
- FDA extends Leqembi Iqlik review period to August 24
- Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.
- BioArctic publishes the Annual Report and Sustainability Report for 2025
- The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
- New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
- Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
- Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
- Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
- Leqembi included in China's commercial insurance innovative drug list
- New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
- New data on lecanemab to be presented at CTAD conference
- Leqembi® approved for IV maintenance treatment in the United Kingdom
- Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
- Health Canada Grants Authorization for Leqembi® (lecanemab)
- Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
- Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
- Leqembi® approved for IV maintenance treatment in China
- Leqembi® approved for the treatment of early Alzheimer's disease in Australia
- BioArctic: Gunilla Osswald awarded Uppsala University Alumnus of the year 2025
- Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status
- BioArctic signs $30 million deal with Novartis for brain drug technology
- BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties
- Leqembi® (lecanemab) launched in the EU today
- Invitation to presentation of BioArctic's second quarter report for April - June 2025 on August 28 at 9.30 a.m. CET
- Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
- BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with consistent safety profile
- Lecanemab four-year efficacy and safety data to be presented at AAIC 2025
- The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association
- BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize
B and BIOA Related Press Releases
Go Back- Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
- Bulletin from the Annual General Meeting in BioArctic AB (publ)
- BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day
- Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)
- Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET
- Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.
- BioArctic publishes the Annual Report and Sustainability Report for 2025
- The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
- New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
- Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
- Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
- Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
- Leqembi included in China's commercial insurance innovative drug list
- New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
- New data on lecanemab to be presented at CTAD conference
- Leqembi® approved for IV maintenance treatment in the United Kingdom
- Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
- Health Canada Grants Authorization for Leqembi® (lecanemab)
- Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
- Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
- Leqembi® approved for IV maintenance treatment in China
- Leqembi® approved for the treatment of early Alzheimer's disease in Australia
- BioArctic: Gunilla Osswald awarded Uppsala University Alumnus of the year 2025
- Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status
- BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties
- Leqembi® (lecanemab) launched in the EU today
- Invitation to presentation of BioArctic's second quarter report for April - June 2025 on August 28 at 9.30 a.m. CET
- Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
- BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with consistent safety profile
- Lecanemab four-year efficacy and safety data to be presented at AAIC 2025
- The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association
- BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize
